Viatris seeks to empower Australians to live healthier at every stage of life by providing access to high quality, trusted medicines.

Viatris is a new kind of global healthcare company formed in 2020. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to improve patient outcomes.

Our Australian head office is based in Sydney, NSW. We are headquartered in the U.S. with global centres in India and China and representation in over 165 countries and territories. We have a global workforce of approximately 37,000 people and approximately 40 manufacturing sites.

With approximately 800 employees, our Australian business is a prime example of our scientific, manufacturing and distribution expertise with leading regulatory, medical and commercial capabilities which bring quality medicines to patients when and where they need them. Our local manufacturing capabilities, from our origins as generic manufacturer Alphapharm, allows us to produce and supply high quality medicines for Australia as well as for export.

Two thirds of the medicines we supply in Australia are manufactured within our global network and at Carole Park, Queensland, meaning we can respond with speed and agility to address the healthcare needs of the country.

Our global portfolio has more than 1,400 molecules across a broad range of therapeutic areas spanning noncommunicable and infectious diseases.

Our diverse portfolio delivers trusted, quality medicines that treat nine out of ten of the World Health Organization’s (WHO) leading causes of death and more than 200 of our medicines are on the WHO Essential Medicines List.

We have a broad portfolio in Australia with over 1,000 registered products which are delivered directly through our warehouse. These include key innovation products, prescription and OTC medicines – both branded and generics. Our manufacturing facility in Queensland produces billions of doses of medicine every year.

We are a leading supplier of medicines to the Australian Pharmaceutical Benefits Scheme (PBS) and 43 out of the top 50 PBS products sold by volume are Viatris medicines.

We are committed to responsible and sustainable operations, recognising that our actions affect our stakeholders and the communities we serve. This spans across patient health, employee health, community health, environmental health and global public health.

We believe in supporting patients with more than our medicines alone. Initiatives include:

MyEpiPen^® patient support program
Australia has the largest program globally with over 40,000 members. The program includes reminders to prompt patients to get a new prescription, a free trainer device, “how to use” cards to keep at home and share with friends and family and video explainers in 25 languages.

Ferro-grad resource kit
Patients who are starting on our iron supplement Ferro-grad for iron deficiency are provided with with a resource kit which includes patient support materials and education to help them understand and manage their condition.

Supporting cancer research
Together with the QIMR Berghofer Medical Research Institute, Viatris supports research to assist with the earlier diagnosis and treatment of panreatic cancer.

We are committed to environmentally responsible conduct and have policies and procedures to systematically minimise our environmental footprint. Our integrated, comprehensive approach focuses on managing our water, air emissions, waste, climate change and energy impact. Ninety-five per cent of pharmaceutical waste has been diverted from landfills to incineration or energy recovery facilities.